Table 3.

Association Between Prevalent AF and eGFRcys, eGFRcreat, and eGFRcreat‐cys at Baseline, eGFRcreat With Age, and Incident Reduced Kidney Function (n=9697)

	Total N	β (95% CI), Model 1	β (95% CI), Model 2
Outcome: eGFR at baseline, cross‐sectional
eGFRcys
No prevalent AF	9288	Reference	Reference
Prevalent AF	409	−5.46 (−6.89 to −4.03)*	−4.24 (−5.68 to −2.81)*
eGFRcreat
No prevalent AF	9288	Reference	Reference
Prevalent AF	409	−2.80 (−4.07 to −1.53)*	−1.93 (−3.23 to −0.63)*
eGFRcreat‐cys
No prevalent AF	9288	Reference	Reference
Prevalent AF	409	−4.46 (−5.72 to −3.19)*	−3.36 (−4.64 to −2.07)*
Outcome: eGFRcreat with age, longitudinal †
No prevalent AF	9288	Reference	Reference
Prevalent AF	409	−4.08 (−5.29 to −2.86)*	−2.85 (−4.10 to −1.60)*

	Events/ total n	HR (95% CI), Model 1	HR (95% CI), Model 2
Outcome: incident reduced kidney function, longitudinal ‡
No prevalent AF	2535/8422	Reference	Reference
Prevalent AF	157/306	1.50 (1.27 to 1.77)*	1.33 (1.12 to 1.58)*

Model 1 is adjusted for age, sex, and Rotterdam Study cohort. Model 2 is additionally adjusted for educational level, BMI, smoking, alcohol, serum cholesterol, diabetes, physical activity, and use of cardiac medication. Linear regression models were used to investigate the associations between prevalent AF and eGFR at baseline. Linear mixed models were used to investigate the association between prevalent AF and eGFRcreat with age. Cox proportional‐hazards models were used to investigate the associations between prevalent AF and incident reduced kidney function. AF indicates atrial fibrillation; BMI, body mass index; eGFR, estimated glomerular filtration rate; eGFRcreat, eGFR based on serum creatinine; eGFRcreat‐cys, eGFR based on serum creatinine and serum cystatin C; eGFRcys, eGFR based on serum cystatin C; and HR, hazard ratio.

^* P<0.05.

^† Total of 70 687 repeated assessments of eGFR (median of 5 repeated assessments).

^‡ Participants with prevalent reduced kidney function were excluded from the analysis (n=969).